Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Yu Jia Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis-Pistofidis, Robert A. Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu-Tzu Tai, Francois Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial

Blood (2021) 137 (17): 2360–2372.

https://doi.org/10.1182/blood.2020005885

Published: 2021

Includes: Supplemental data

Journal Articles

In-Hospital Mortality and Morbidity Among Patients Presenting with Intracranial Hemorrhage: A Single Center's Experience with Vitamin K Antagonists and the Direct Oral Anticoagulants

Christopher Cipkar, MD BSc, Sujitha Srinathan, Philip Chiang, BMSc, Lana A Castellucci, MD FRCPC, MSc

Blood (2019) 134 (Supplement_1): 3668.

https://doi.org/10.1182/blood-2019-131769

Published: 2019

Journal Articles

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

Paul F Lindholm, MD, Hau C. Kwaan, MD PhD, Andrew M Naidech, MDMSPH

Blood (2019) 134 (Supplement_1): 4886.

https://doi.org/10.1182/blood-2019-128370

Published: 2019

Journal Articles

Bone Marrow Hematopoietic Connexin 43 Is Required for Mitotransfer and AMPK Dependent Mesenchymal Microenvironment Regeneration after Irradiation

Abhishek K Singh, PhD, Karin Golan, PhD, Mark J Althoff, BS, Ekaterina Petrovich-Kopitman, Ashley M Wellendorf, B.S., Fatima Mohmoud, B.S., Mayla Bertagna, MSc, Daniel Gonzalez-Nieto, PhD, Luis C Barrio, MD PhD, Tsvee Lapidot, PhD, Jose A Cancelas, MD PhD

Blood (2018) 132 (Supplement 1): 872.

https://doi.org/10.1182/blood-2018-99-118292

Published: 2018

Journal Articles

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

Vibe Skov, PhD, Lasse Kjær, PhD, Mads Thomassen, PhD, Steffen Koschmieder, MD, Julia Czech, Nicolas Chatain, PhD, Niels Pallisgaard, Sabrina Cordua, MD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4327.

https://doi.org/10.1182/blood-2018-99-119158

Published: 2018

Journal Articles

A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients

Maria Ortiz, Fadi Towfic, PhD, Mehmet Kemal Samur, PhD, Erin Flynt, In Sock Jang, PhD, Kai Wang, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Matthew Trotter, PhD, Gareth Morgan, MD, Nikhil Munshi, MD, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2018-99-117114

Published: 2018

Journal Articles

Glia Maturation Factor-Gamma Modulates M2 Activation of Macrophage Via Suppression of Mitochondria Function

Wulin Aerbajinai, MD PhD, Jie Liu, Chutima Kumkhaek, Jianqiong Zhu, Kyung Chin, Griffin Rodgers, MD

Blood (2017) 130 (Supplement 1): 998.

https://doi.org/10.1182/blood.V130.Suppl_1.998.998

Published: 2017

Journal Articles

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Blood (2017) 130 (Supplement 1): 2771.

https://doi.org/10.1182/blood.V130.Suppl_1.2771.2771

Published: 2017

Journal Articles

The Role of VWF, FVIII, ADAMTS13 and Inflammatory Response in the Outcome of Acute Ischemic Stroke Mechanical Thrombectomy Procedure

Jaromir Gumulec, MD, Václav Procházka, MD, PhD, Tomáš Jonszta, MD, PhD, Daniel Czerný, MD, Martin Roubec, MD, Jirka Mačák, MD, PhD, Petra Kovářová, Mgr., Ivo Lochman, PhD, David Kaspřák, PhD, Roman Hajek

Blood (2017) 130 (Supplement 1): 3613.

https://doi.org/10.1182/blood.V130.Suppl_1.3613.3613

Published: 2017

Journal Articles

Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke (CoBIS): Clinical Outcomes from a Phase 1 Safety Study

Joanne Kurtzberg, MD, Jesse D Troy, PhD, Ellen Bennett, PhD, Samir Belagaje, MD, Elizabeth J. Shpall, MD, Jonathan Wiese, MSN, RN, CNL, John Volpi, MD, Daniel Laskowitz, MD

Blood (2016) 128 (22): 2284.

https://doi.org/10.1182/blood.V128.22.2284.2284

Published: 2016

Journal Articles

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Blood (2016) 128 (22): 1929.

https://doi.org/10.1182/blood.V128.22.1929.1929

Published: 2016

Journal Articles

A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

Jesus G. Berdeja, MD, Tara B. Gregory, MD, Edward Faber, Jeffrey Matous, MD, Lowell Hart, MD, Joseph R. Mace, MD, Edward R. Arrowsmith, MD MPH, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 4530.

https://doi.org/10.1182/blood.V128.22.4530.4530

Published: 2016

Journal Articles

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Christine Dosquet, Stephane Giraudier, Marie-Hélène Schlageter, Jean-Christophe Ianotto, Mohammed A. Yassin, Nader Al-Dewik, Serge Carillo, Eric Legouffe, Valerie Ugo, Christine Chomienne, Jean-Jacques Kiladjian

Blood (2015) 126 (24): 2585–2591.

https://doi.org/10.1182/blood-2015-07-659060

Published: 2015

Journal Articles

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Andreas Hochhaus, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Richard A. Larson, MD, Lilia Taningco, MSc, Weiping Deng, Hans D Menssen, MD PhD, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 2781.

https://doi.org/10.1182/blood.V126.23.2781.2781

Published: 2015

Journal Articles

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas C.P. Cross, PhD, Andrzej Hellman, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Medina Almeida, Arpad Illes, MD PhD, Cristalina Fernandez, Luca Dezzani, Angela Pellegrino, Chiara Costantini, Claudia Walasek, Giuseppe Saglio, Juan Luis Steegmann, MD, Michele Baccarani

Blood (2015) 126 (23): 4040.

https://doi.org/10.1182/blood.V126.23.4040.4040

Published: 2015

Journal Articles

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Blood (2015) 126 (23): 4226.

https://doi.org/10.1182/blood.V126.23.4226.4226

Published: 2015

Journal Articles

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Suzanne Trudel, MD, Darrell White, MD, Martin Gyger, MD, Jonahtan Kaufmann, MD, Andrzej Jakubowiak, MD PhD, Engin Gul, BSc, Lisa W Le, MSc, Zhihua Li, Donna Reece, Vishal Kukreti, MD FRCPC, Richard LeBlanc

Blood (2015) 126 (23): 4234.

https://doi.org/10.1182/blood.V126.23.4234.4234

Published: 2015

Journal Articles

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francisco Cervantes, Nelson Spector, MD PhD, Brian Leber, MD, Susan Branford, PhDFFSc (RCPA), Tara A. Glynos, BS, Sandip Acharya, MSc, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 4029.

https://doi.org/10.1182/blood.V126.23.4029.4029

Published: 2015

Journal Articles

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Blood (2015) 126 (23): 1597.

https://doi.org/10.1182/blood.V126.23.1597.1597

Published: 2015

Journal Articles

A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts

Jesus G. Berdeja, MD, Tara B. Gregory, MD, Edward A. Faber, DO, Jeffrey V. Matous, MD, Lowell L. Hart, MD, Joseph R. Mace, MD, James D. Peyton, MD, James H. Essell, MD, Edward R. Arrowsmith, MD MPH, Ian W. Flinn, MD PhD

Blood (2015) 126 (23): 1825.

https://doi.org/10.1182/blood.V126.23.1825.1825

Published: 2015

NARROW

Progression signature underlies clonal evolution and dissemination of multiple myeloma

In-Hospital Mortality and Morbidity Among Patients Presenting with Intracranial Hemorrhage: A Single Center's Experience with Vitamin K Antagonists and the Direct Oral Anticoagulants

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

Bone Marrow Hematopoietic Connexin 43 Is Required for Mitotransfer and AMPK Dependent Mesenchymal Microenvironment Regeneration after Irradiation

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients

Glia Maturation Factor-Gamma Modulates M2 Activation of Macrophage Via Suppression of Mitochondria Function

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

The Role of VWF, FVIII, ADAMTS13 and Inflammatory Response in the Outcome of Acute Ischemic Stroke Mechanical Thrombectomy Procedure

Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke (CoBIS): Clinical Outcomes from a Phase 1 Safety Study

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only